Can a nap room and fancy glasses save night shift nurses from burnout?
NCT ID NCT06829979
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This small pilot study tested whether giving night shift nurses access to a napping/relaxation room and blue/green light blocking glasses is practical and might improve their health and reduce burnout. Five nurses from one hospital took part. The study focused on whether nurses would use these tools and complete the surveys and saliva samples, not on proving they work.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- access to napping/relaxation room and blue/green light blocking glasses
- What this could lead to
- If it works, this could point toward simple, low-cost ways to help night shift nurses feel healthier and less burned out.
- What could go wrong
- This is a very small pilot study with only 5 participants, so results may not apply to all nurses. It only tests feasibility, not effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Shadyside
Pittsburgh, Pennsylvania, 15232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test